Plasma cytokine analysis in patients with advanced extremity melanoma undergoing isolated limb infusion

Annals of Surgical Oncology

Volumn 20, Issue 4, 2013, Pages 1128-1135

  Shetty, Gina ^a   Beasley, Georgia M ^a   Sparks, Sara ^a   Barfield, Michael ^a   Masoud, Melanie ^a   Mosca, Paul J ^a   Pruitt, Scott K ^a   Salama, April K S ^a   Chan, Cliburn ^a   Tyler, Douglas S ^a   Weinhold, Kent J ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; DACTINOMYCIN; EPIDERMAL GROWTH FACTOR; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 12P40; INTERLEUKIN 17; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MELPHALAN; MONOCYTE CHEMOTACTIC PROTEIN 1; SORAFENIB; VASCULOTROPIN;

ADVANCED CANCER; AGED; BODY WEIGHT; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; COMPARTMENT SYNDROME; CONFERENCE PAPER; CONTROLLED STUDY; FASCIOTOMY; FEMALE; FOLLOW UP; HUMAN; INOPERABLE CANCER; MAJOR CLINICAL STUDY; MALE; MELANOMA; MUSCLE NECROSIS; PHARMACOKINETICS; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; CASE-CONTROL STUDIES; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; CYTOKINES; EXTREMITIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MELANOMA; MELPHALAN; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; SKIN NEOPLASMS; SURVIVAL RATE;

EID: 84875208869     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-012-2785-5     Document Type: Conference Paper

References (31)

1. TW Pawlik MI Ross MM Johnson, et al. 2005 Predictors and natural history of in-transit melanoma after sentinel lymphadenectomy Ann Surg Oncol. 11 1612 1661
2. D van Poll JF Thompson JG McKinnon, et al. 2005 A sentinel node biopsy procedure does not increase the incidence of in-transit recurrence in patients with primary melanoma Ann Surg Oncol. 12 597 608 16021534 10.1245/ASO.2005.08. 012
3. AK Raymond GM Beasley G Broadwater, et al. 2011 Current trends in regional therapy for melanoma: lessons learned from 225 regional chemotherapy treatments between 1995 and 2010 at a single institution J Am Coll Surg. 213 306 316 21493111 10.1016/j.jamcollsurg.2011.03.013
4. GM Beasley A Caudle RP Petersen, et al. 2009 A multi-institutional experience of isolated limb infusion: defining response and toxicity in the United States J Am Coll Surg. 208 706 716 19476821 10.1016/j.jamcollsurg.2008. 12.019
5. P Lindner A Doubrovsky PCA Kam, et al. 2002 Prognostic factors after isolated limb infusion with cytotoxic agents for melanoma Ann Surg Oncol. 9 127 136 11888868
6. HM Kroon M Moncrieff PCA Kam, et al. 2008 Outcomes following isolated limb infusion for melanoma: a 14-year experience Ann Surg Oncol. 15 3003 3013 18509706 10.1245/s10434-008-9954-6
7. GM Beasley RP Petersen JS Yoo, et al. 2008 Isolated limb infusion for in-transit malignant melanoma of the extremity: a well tolerated but less effective alternative to hyperthermic isolated limb perfusion Ann Surg Oncol. 15 2195 2205 18528730 10.1245/s10434-008-9988-9
8. JF Thompson JA Hunt KF Shannon, et al. 1997 Frequency and duration of remission after isolated limb perfusion for melanoma Arch Surg. 132 903 907 9267277 10.1001/archsurg.1997.01430320105017 1:STN:280:DyaK2svht1Khtw%3D%3D
9. CK Augustine SH Jung I Sohn, et al. 2010 Gene expression signatures as a guide to treatment strategies for in-transit metastatic melanoma Mol Cancer Ther. 9 779 790 20371714 10.1158/1535-7163.MCT-09-0764 1:CAS:528: DC%2BC3cXktlCqtro%3D
10. M Hong AL Puaux C Huang, et al. 2011 Chemotherapy induces intratumoral expression of chemokines in cutaneous melanoma, favoring T cell infiltration and tumor control Cancer Res. 71 6997 21948969 10.1158/0008-5472.CAN-11-1466 1:CAS:528:DC%2BC3MXhsVKhu7fN
11. M Sznol 2011 Molecular markers of response to treatment for melanoma Cancer J. 17 127 133 21427556 10.1097/PPO.0b013e318212dd5a 1:CAS:528: DC%2BC3MXmtVKnsLY%3D
12. A Boni AP Cogdill P Dang, et al. 2010 Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function Cancer Res. 70 5213 5219 20551059 10.1158/0008-5472.CAN-10-0118 1:CAS:528:DC%2BC3cXot1WlurY%3D
13. L Galluzzi L Senovilla L Zitvogel, et al. 2012 The secret ally: immunostimulation by anticancer drugs Nat Rev Drug Discov. 11 215 233 22301798 10.1038/nrd3626 1:CAS:528:DC%2BC38Xhs1Gitb4%3D
14. A Nardin WC Wong C Tow, et al. 2011 Dacarbazine promotes stromal remodeling and lymphocyte infiltration in cutaneous melanoma lesions J Invest Dermatol. 131 1896 1905 21654834 10.1038/jid.2011.128 1:CAS:528: DC%2BC3MXhtVWrs7%2FL
15. M Donepudi VM Jovasevic P Raychaudhuri MB Mokyr 2003 Melphalan-induced up-regulation of B7-1 surface expression on normal splenic B cells Cancer Immunol Immunother. 52 162 170 12649745 1:CAS:528:DC%2BD3sXit1Kit7o%3D
16. M Sabatino S Kim-Schulze MC Panelli, et al. 2009 Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy J Clin Oncol. 27 2645 2652 19364969 10.1200/JCO.2008.19. 1106 1:CAS:528:DC%2BD1MXnslWit7k%3D
17. ZR Yurkovetsky JM Kirkwood HD Edington, et al. 2007 Multiplex analysis of serum cytokines in melanoma patients treated with interferon-alpha 2b Clin Cancer Res. 13 2422 2428 17438101 10.1158/1078-0432.CCR-06-1805 1:CAS:528:DC%2BD2sXkt1enu7o%3D
18. CM Balch JE Gershenwald SJ Soong, et al. 2009 Final version of 2009 AJCC melanoma staging and classification J Clin Oncol. 27 6199 6206 19917835 10.1200/JCO.2009.23.4799
19. P Therasse SG Arbuck EA Eisenhauer, et al. 2000 New guidelines to evaluate the response to treatment in solid tumors J Natl Cancer Inst. 92 205 216 10655437 10.1093/jnci/92.3.205 1:STN:280:DC%2BD3c7it1Gitg%3D%3D
20. N McMahon TY Cheng GM Beasley, et al. 2009 Optimizing melphalan pharmacokinetics in regional melanoma therapy: does correcting for ideal body weight alter regional response or toxicity? Ann Surg Oncol. 16 953 961 19184236 10.1245/s10434-008-0288-1 1:STN:280:DC%2BD1M7ptFKrsg%3D%3D
21. GM Beasley JC Riboh CK Augustine, et al. 2011 A prospective multi-center phase II trial of systemic ADH-1 in combination with melphalan via isolated limb infusion (M-ILI) in patients with advanced extremity melanoma J Clin Oncol. 29 1210 1215 21343562 10.1200/JCO.2010.32.1224 1:CAS:528:DC%2BC3MXmtVyrsb4%3D
22. GM Beasley AP Coleman N McMahon, et al. 2012 A phase I multi-institutional study of systemic sorafenib in conjunction with regional melphalan for in-transit melanoma of the extremity Ann Surg Oncol. 19 3896 3905 22549288 10.1245/s10434-012-2373-8 1:STN:280:DC%2BC38rpsFaluw%3D%3D
23. H Ehrsson S Eksborg A Lindfors 1986 Quantitative determination of melphalan in plasma by liquid chromatography after derivatization with N-acetylcysteine J Chromatogr. 380 220
24. JA Freedman DS Tyler JR Nevins CK Augustine 2011 Use of gene expression and pathway signatures to characterize the complexity of human melanoma Am J Pathol. 178 2513 2522 21641377 10.1016/j.ajpath.2011.02.037 1:CAS:528: DC%2BC3MXoslOgu7g%3D
25. KA Yao EC Hsueh R Essner, et al. 2003 Is sentinel lymph node mapping indicated for isolated local and in-transit recurrent melanoma? Ann Surg. 238 743 747 14578738 10.1097/01.sla.0000094440.50547.1d
26. EP Tjin D Konijnenberg G Krebbers, et al. 2011 T cell immune function in tumor, skin and peripheral blood of advanced stage melanoma patients: implications for immunotherapy Clin Cancer Res. 17 5736 5747 21750202 10.1158/1078-0432.CCR-11-0230 1:CAS:528:DC%2BC3MXhtFSmtb%2FK
27. VP Balachandran MJ Cavnar S Zeng, et al. 2011 Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido Nat Med. 17 1094 1100 21873989 10.1038/nm.2438 1:CAS:528:DC%2BC3MXhtV2gtLnE
28. L Rivoltini M Carrabba V Huber, et al. 2002 Immunity to cancer: attack and escape in T lymphocyte-tumor cell interaction Immunol Rev. 188 97 113 12445284 10.1034/j.1600-065X.2002.18809.x 1:CAS:528:DC%2BD38Xps1Oqsrg%3D
29. + T-cell recruitment Cancer Res. 69 3077 3085 19293190 10.1158/0008-5472.CAN-08-2281 1:CAS:528:DC%2BD1MXjvVWitr8%3D
30. G Erdag JT Schaefer ME Smolkin, et al. 2012 Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma Cancer Res. 72 1070 1080 22266112 10.1158/0008-5472.CAN-11-3218 1:CAS:528:DC%2BC38Xjt1Wju7Y%3D
31. M Obeid A Tesniere F Ghiringhelli, et al. 2007 Calreticulin exposure dictates the immunogenicity of cancer cell death Nat Med. 13 54 61 17187072 10.1038/nm1523 1:CAS:528:DC%2BD2sXhvFWisw%3D%3D